

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-7. Canceled

8. (Currently Amended) A cyclic peptide modulating agent according to claim 7, wherein the cyclic peptide has having the formula:

(Z₁)-(Y₁)-(X₁)-(W)-(X₂)-(Y₂)-(Z₂);

wherein W is thea tri-peptide selected from the group consisting of EEY, DDK, EAQ, DAE, NEN, ESE, DSG, DEN, EPK, DAN, EEF, NDV, DET, DPK, DDT, DAN, DKF, DEL, DAD, NNK, DLV, NRD, DPS, NQK, NRN, NKD, EKD, ERD, DPV, DSV, DLY, DSN, DSS, DEK and NEK;

wherein X₁ is C, and X₂ is E; ~~are optional, and if present, are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds, and wherein X₁ and X₂ independently range in size from 0 to 10 residues, such that the sum of residues contained within X₁ and X₂ ranges from 1 to 12;~~

wherein Y₁ and Y₂ are independently selected from the group consisting of amino acid residues, and wherein a covalent bond is formed between residues Y₁ and Y₂; and

wherein Z₁ and Z₂ are optional, and if present, are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds,

and wherein the agent can modulate cadherin-5-mediated endothelial cell adhesion.

9.-104. Canceled

105. (Currently Amended) A modulating agent according to ~~any one of claims 81-4 or 12-14~~ linked to a drug.

106. (Currently Amended) A modulating agent according to ~~any one of claims 81-4 or 12-14~~ linked to a detectable marker.

107. (Currently Amended) A modulating agent according to ~~any one of claims 81-4 or 12-14~~ linked to a targeting agent.

108. (Currently Amended) A modulating agent according to ~~any one of claims 81-4 or 12-14~~ linked to a support material.

109. (Original) A modulating agent according to claim 108, wherein the support material is a polymeric matrix.

110. (Original) A modulating agent according to claim 108, wherein the support material is selected from the group consisting of plastic dishes, plastic tubes, sutures, membranes, ultra thin films, bioreactors and microparticles.

111. (Currently Amended) A modulating agent according to ~~any one of claims 81-4 or 12-14~~, further comprising one or more of:

(a) a CAR sequence that is specifically recognized by an adhesion molecule other than ~~the nonclassical cadherin~~ cadherin-5; and/or

(b) an antibody or antigen-binding fragment thereof that specifically binds to a CAR sequence that is specifically recognized by an adhesion molecule other than ~~the nonclassical cadherin~~ cadherin-5.

112. (Original) A modulating agent according to claim 111, wherein the adhesion molecule is selected from the group consisting of cadherins, integrins, occludin,

claudins, desmogleins, desmocollins, protocadherins, cadherin-related neuronal receptors, fibronectin, laminin, claudins and other extracellular matrix proteins.

113. (Currently Amended) A composition comprising a modulating agent according to ~~any one of claims 8-14 or 12-14~~ in combination with a pharmaceutically acceptable carrier.

114. (Original) A composition according to claim 113, further comprising a drug.

115. (Original) A composition according to claim 113, wherein the modulating agent is present within a sustained-release formulation.

116. (Currently Amended) A pharmaceutical composition according to claim 115, further comprising a modulator of cell adhesion that comprises one or more of:

(a) a CAR sequence that is specifically recognized by an adhesion molecule other than ~~the nonclassical cadherin~~ cadherin-5; and/or

(b) an antibody or antigen-binding fragment thereof that specifically binds to a CAR sequence that is specifically recognized by an adhesion molecule other than ~~the nonclassical cadherin~~ cadherin-5.

117. (Original) A pharmaceutical composition according to claim 116, wherein the adhesion molecule is selected from the group consisting of cadherins, integrins, occludin, claudins, desmogleins, desmocollins, protocadherins, cadherin-related neuronal receptors, fibronectin, laminin and other extracellular matrix proteins.